OTC Proposals Need To Protect End-Users Better

16 Oct 2009

Proposals to regulate over-the-counter derivatives do not go far enough in exempting corporate OTC end-users from margining or capital provisions, according to Jiro Okochi, ceo and co-founder of Reval, a derivative risk management provider.

Proposals to regulate over-the-counter derivatives do not go far enough in exempting corporate OTC end-users from margining or capital provisions, according to Jiro Okochi, ceo and co-founder of Reval, a derivative risk management provider. Okochi said the measures working their way through Congress need further improvement, saying, “I ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial